JMP Securities maintains CorMedix's rating at $19.00, while Truist Financial and Royal Bank of Canada lower their price targets.
JMP Securities reiterates its rating for CorMedix (NASDAQ:CRMD) at $19.00. Other firms have also issued reports, with Truist Financial lowering its price target from $18.00 to $14.00 and Royal Bank of Canada reducing its target from $10.00 to $9.00. Needham & Company LLC maintained a buy rating and set a $10.00 price target. CorMedix has a market cap of $320.09m, a P/E ratio of -6.35, and a beta of 1.86.
April 13, 2024
3 Articles